摘要
目的 探讨磷酸西格列汀与二甲双胍联合应用对2型糖尿病患者胰岛素抵抗与微炎性反应的影响。方法 方便选择2020年3月—2021年2月菏泽市第二人民医院收治的2型糖尿病患94例,以随机数表法将其分为两组。对照组47例应用二甲双胍治疗,研究组47例在此基础上应用磷酸西格列汀治疗。治疗前与治疗8周时,观察与对比两组的血糖指标[2 h餐后血糖(2 hPG)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗指标[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)]、微炎性反应指标[C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)]以及不良反应。结果 治疗后研究组2 hPG(10.23±3.00)mmol/L、FPG(7.03±2.57)mmol/L、HbA1c(7.52±2.64)%较对照组(13.05±4.08)mmol/L、(8.94±2.44)mmol/L、(9.64±2.48)%低,差异有统计学意义(t=3.818、3.695、4.013,P<0.05)。治疗后研究组HOMA-IR(3.08±1.83)较对照组(4.51±2.04)低,FINS(14.36±3.89)mU/L较对照组(11.55±3.05)mU/L高,差异有统计学意义(t=3.577、3.897,P<0.05)。治疗后研究组CRP(4.00±2.54)ng/mL、TNF-α(43.52±8.02)ng/mL较对照组(6.78±2.49)、(58.00±7.89)ng/mL低,差异有统计学意义(t=5.358、8.824,P<0.05)。两组不良反应发生率均为4.26%,差异无统计学意义(χ^(2)=0.261,P>0.05)。结论 2型糖尿病患者采用磷酸西格列汀与二甲双胍联合治疗效果确切,适于临床推广。
Objective To investigate the effect of combined application of sitagliptin phosphate and metformin on insulin resistance and micro-inflammatory response in patients with type 2 diabetes mellitus.Methods A total of 94 patients with type 2 diabetes admitted to Heze Second People's Hospital from March 2020 to February 2021 were conveniently selected.They were divided into two groups by random number table method.47 cases in the control group were treated with metformin,and 47 cases in the study group were treated with sitagliptin phosphate on this basis.Before treatment and 8 weeks after treatment,the blood glucose indexes[2-hour postprandial blood glucose(2 hPG),fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c)],insulin resistance indexes[fasting insulin(FINS),insulin resistance index(HOMA-IR)],micro-inflammatory response indicators[C-reactive protein(CRP),tumor necrosis factorα(TNF-α)],and adverse reactions were observed and compared.Results After treatment,2 hPG(10.23±3.00)mmol/L,FPG(7.03±2.57)mmol/L,HbA1c(7.52±2.64)%of the study group were lower than those of the control group(13.05±4.08)mmol/L,(8.94±2.44))mmol/L,(9.64±2.48)%,and the difference was statistically significant(t=3.818,3.695,4.013,P<0.05).After treatment,the HOMA-IR(3.08±1.83)of the study groups was lower than that of the control group(4.51±2.04),and the FINS(14.36±3.89)mU/L was higher than that of the control group(11.55±3.05)mU/L,and the difference was statistically significant(t=3.577,3.897,P<0.05).After treatment,CRP(4.00±2.54)ng/mL and TNF-α(43.52±8.02)ng/mL in the study group were lower than those in the control group(6.78±2.49)ng/mL and(58.00±7.89)ng/mL,and the difference was statistically significant(t=5.358,8.824,P<0.05).The incidence of adverse reactions in both groups was 4.26%,the difference was statistically significant(χ^(2)=0.261,P>0.05).Conclusion The combined treatment of sitagliptin phosphate and metformin in patients with type 2 diabetes is effective and suitable for clinical promotion.
作者
沈德坤
SHEN Dekun(Department of Pharmacy,Heze Second People's Hospital,Heze,Shandong Province,274000 China)
出处
《中外医疗》
2023年第5期120-123,137,共5页
China & Foreign Medical Treatment
关键词
磷酸西格列汀
二甲双胍
2型糖尿病
血糖
胰岛素抵抗
微炎性反应
Sitagliptin phosphate
Metformin
Type 2 diabetes mellitus
Blood glucose
Insulin resistance
Microinflammatory response
